Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-09-28 02:32:55 - browse：16437

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： 'Investigate these claims': UFO transparency at center of House hearing

WSS

CDC Director Mandy Cohen on transparency, trust, and health

The battle over 'scope creep' and who gets to be called 'doctor'

'Investigate these claims': UFO transparency at center of House hearing

New Alzheimer's drugs heat up race for early detection blood tests

President Biden's budget: Here's what you might have missed

Biden warns of ‘dark winter’ during final presidental debate

focus

Wikipedia

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

A new crop of companies is reshaping the health data economy

George Santos makes 1st court appearance after pleading not guilty to 13 counts

STAT Report: Patient voices and perspectives

Activists slam private health insurers over coverage restrictions

Medicare coverage of Wegovy, once blocked, now looks possible

Tori Bowie and the unacceptable rates of Black maternal death

President Biden's budget: Here's what you might have missed

Moonlake's readout produced a cash windfall. Risks remain

Ebola: Gilead Sciences antiviral shows promise as new treatment

entertainment

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Boston's new lab space is opening empty

A new crop of companies is reshaping the health data economy

How doctors’ personal politics affect patients

Boston's new lab space is opening empty

'Investigate these claims': UFO transparency at center of House hearing

focus

Wikipedia

knowledge

focus